02:10 , Feb 11, 2017 |  BioCentury  |  Product Development

Form(ulation) follows function

A clinical study of two formulations of marketed drug Linzess linaclotide supports Ironwood Pharmaceuticals Inc. ’s hypothesis that pain in irritable bowel syndrome with constipation is not due to constipation alone, but also to hypersensitive...
21:05 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Colonic-release linaclotide: Ph IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 532 adult patients with IBS-C showed that once-daily 300 µg oral colonic-release-1 formulation of linaclotide (CR1) for 12 weeks led to a greater proportion of...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Oct 3, 2016 |  BioCentury  |  Strategy

Combo deals

Allergan plc's two NASH acquisitions give it the second biggest pipeline for the indication and enough mechanisms to develop in-house combinations that could target multiple drivers of the disease pathophysiology. Together, Allergan's Sept. 20 deals...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Colonic-release linaclotide: Phase IIb started

Ironwood and Allergan began a double-blind, double-dummy, placebo-controlled Phase IIb trial to compare 2 oral colonic-release formulations of linaclotide ( CR1 and CR2 ) once daily for 12 weeks vs. 290 ug oral linaclotide in...